Cargando…

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nan, Feifei, Fu, Xiaorui, Chen, Xinfeng, Li, Ling, Li, Xin, Wu, Jingjing, Feng, Xiaoyan, Wu, Xiaolong, Yan, Jiaqin, Zhang, Mingzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399606/ https://www.ncbi.nlm.nih.gov/pubmed/36032118 http://dx.doi.org/10.3389/fimmu.2022.929221

Ejemplares similares

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
por: Andrea, Alain E., et al.
Publicado: (2022)

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing
por: Zhang, Tingting, et al.
Publicado: (2022)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy
por: Li, Wenshuai, et al.
Publicado: (2023)

AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma
por: Yan, Jiaqin, et al.
Publicado: (2018)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020)

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
por: Sun, Yuanyuan, et al.
Publicado: (2020)

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
por: Guedan, Sonia, et al.
Publicado: (2018)

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors
por: Mi, Juan, et al.
Publicado: (2022)

How can Cytokine-induced killer cells overcome CAR-T cell limits
por: Cappuzzello, Elisa, et al.
Publicado: (2023)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
por: Li, Ling, et al.
Publicado: (2018)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
por: Wu, Xiaolong, et al.
Publicado: (2022)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
por: Miao, Lele, et al.
Publicado: (2021)

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial
por: Wu, Jingjing, et al.
Publicado: (2018)

Strategies to overcome DC dysregulation in the tumor microenvironment
por: Mestrallet, Guillaume, et al.
Publicado: (2022)

Co-Expression of miR155 or LSD1 shRNA Increases the Anti-Tumor Functions of CD19 CAR-T Cells
por: Zhang, Jing, et al.
Publicado: (2022)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
por: Ma, Xinran, et al.
Publicado: (2020)

Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance
por: Zhang, Qunfang, et al.
Publicado: (2018)

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
por: Chen, Xiujin, et al.
Publicado: (2022)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
por: Arcangeli, Silvia, et al.
Publicado: (2020)

Road testing new CAR design strategies in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2022)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Recent advances in CAR-T cells therapy for colorectal cancer
por: Qin, Xiaoling, et al.
Publicado: (2022)

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells
por: Zhuang, Xiaoxuan, et al.
Publicado: (2022)

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_287at5tdr8mc4bnp3ujdbsnnud